Antitumor agents

Details Antitumor agents Antitumor agents

2011-05-17

2011-05-17

Cordero Garcia, Marcela M (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S375000

Reexamination Certificate

active

07943568

ABSTRACT:
Compounds and methods useful for the treatment of cancer in subjects in need of such treatment. The compounds are metabolites of the compound FK228 which have been identified as possessing HDAC inhibitory activity and anticancer properties. Further provided are compounds and methods for inducing apoptosis in cancer cells. Further provided are compounds and methods for inhibiting HDAC in cancer cells.

REFERENCES:
patent: 6670326 (2003-12-01), Nagai et al.
patent: 7098186 (2006-08-01), Nagai et al.
patent: 7314862 (2008-01-01), Naoe et al.
Nishino et al. Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases. Organic Letters. 2003. vol. 5, No. 26, pp. 5079-5082.
Somech et al. Histone deacetylase inhibitors—a new tool to treat cancer. Cancer Treatment Reviews. 2004, vol. 30, pp. 461-472.
Furumai et al. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. Cancer Res. 2002, vol. 62, pp. 4916-4921.

Affiliated with

Also associated with

Rating

Antitumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2705838